Member Info for rhwillcoll

I think, now no stock.

0.5 1,000,000 STFL 13:42

0.52 1,000,000 SING 15:20

0.53 1,000,000 SCAP 14:41

0.55 1,000,000 JBER 14:18

0.55 1,000,000 MREX 14:45

0.57 1,000,000 PEEL 14:29

0.57 1,000,000 WINS 14:19

I notice that the share price rise today is "unwarranted" - ie it appears from L2 that all the warrants have now been bought/sold, so with the two great RNSs from last week and great news to come at some early stage - plus excellent revenues starting shortly for capAI in maybe four different capMedia companies, we are in a strong position here.

What specific AI projects in media and medicine could capAI develop through R42 partnership

capAI, through its partnership with R42, is currently reviewing and could develop the following specific AI projects in media and medicine:

AI Book-to-Movie Platform: This project aims to use AI to convert literary works into "cinema-quality screenplay adaptations," streamlining the process of turning books into films.

AI Ageing Vaccine Research: This initiative explores AI-driven approaches to address cellular ageing processes, potentially accelerating the development of vaccines or therapies targeting ageing.

In addition to these, capAI gains access to R42’s broader portfolio, which includes companies such as:

PreView Medical: Specializing in AI for prostate cancer diagnosis.

Healx: Utilizing AI to identify novel drug-disease relationships and scale drug pipelines for patient impact.

These projects exemplify capAI’s focus on transformative AI solutions in both media (content creation and adaptation) and medicine (disease diagnosis, drug discovery, and ageing research).

(My Source: Updated Perplexity App)

CapAI has recently formed a strategic alliance with R42 Group Inc, a US-based, AI-focused venture capital firm led by Professor Ronjon Nag. This partnership gives capAI preferential development rights on selected R42 projects, allowing it to jointly develop early-stage AI opportunities, primarily in the fields of media and medicine, but with the flexibility to expand into broader AI sectors.

The alliance structure means capAI will be involved with:

Selected R42 portfolio companies, particularly those in media and medicine, as capAI has the right of first refusal to participate in their development.

Jointly incubated new AI projects outside the existing portfolios of both firms, leveraging combined expertise and resources.

Some specific project types currently under review for capAI involvement include:

Platforms that convert books into screenplays or interactive games

AI media creators for multi-format content

AI-driven research for aging vaccines

Automated systems to accelerate scientific discovery

R42’s existing investments include companies like PreView Medical (AI for prostate cancer diagnosis) and Healx (AI-driven drug discovery), which illustrates the type of ventures capAI could become involved with through this alliance. However, capAI’s involvement will be determined on a case-by-case basis, with each opportunity assessed for strategic fit and value potential, and no binding capital commitments at this stage.

Additionally, capAI has established a US subsidiary, capMedia, to support its media division activities in the US, including the proposed deployment of its generative AI platform, Author42.

In summary, capAI will be involved with:

R42 Group’s selected AI projects (with a focus on media and medicine)

Jointly incubated new ventures in the AI sector

Its own US subsidiary, capMedia, for media-related AI initiatives

The specific list of companies will evolve as projects are selected and developed under this alliance, but the partnership provides capAI with access to a broad pipeline of early-stage, high-impact AI opportunities.

What specific AI projects in media and medicine could capAI develop through R42 partnership

capAI, through its partnership with R42, is currently reviewing and could develop the following specific AI projects in media and medicine:

AI Book-to-Movie Platform: This project aims to use AI to convert literary works into "cinema-quality screenplay adaptations," streamlining the process of turning books into films.

AI Ageing Vaccine Research: This initiative explores AI-driven approaches to address cellular ageing processes, potentially accelerating the development of vaccines or therapies targeting ageing.

(My source - updated Perplexity AI App)

Islandgirl, yes I agree with you. I like what you posted earlier - so much more to follow, and AI being the modern equivalent of the Industrial Revolution:

Ronjon Nag, comments "I too share the excitement of my fellow directors and I am totally committed to developing capAI into a major player in the AI space, using my own innovations as well as R42 Group resources - more to come on that later. This is my first listed Board position in the UK and I am particularly attracted by being able to offer investors listed exposure to an asset class which is typically reserved for unlisted investors. I am determined to make this venture an outstanding success for all shareholders, both small and large, and I trust that my performance only remuneration package indicates my clear intent to achieve this."

R42 AI and Longevity Club

Welcome to the R42 AI and Longevity Club, a premier membership community dedicated to empowering individuals to optimize their health, wellness, and longevity through cutting-edge AI-driven wellness solutions. Its not a clinic rather a memebership club where we learn together in citizen science mode about works and what doesn't and search for products we can include in the emmebrshiop for pople to try as well as suggest. Join our community of like-minded individuals and take the first step towards a healthier, happier you.

CLICK HERE TO REGISTER INTEREST

Current offers

Please note - currently, membership is free. Below are current R42 Longevity Club offers:

​

Iollo

In-depth metabolomic analysis age biomarker testing.

Uses mass spectrometry to provide a comprehensive overview of various health aspects, such as gut microbiome, aging, immune response, inflammation, hormonal balance, liver and kidney function, bone health, and more. It works by doing a mass spectrometer analysis of blood.

Order kit here (USA only for now).

​

NeuroAge Therapeutics (new offer - Full Body MRI)​

Focused on reversing brain aging to prevent dementia. The company offers the NeuroAge Test, an AI-powered prognostic tool that accurately determines brain biological age and predicts dementia risk up to 30 years in advance.

4 key components: ​1) Brain MRI 2) Cognitive testing (NeuroGames) 3) Proprietary blood biomarkers 4) Genetic analysis.

NOTE: The offers available below are valid for the MRI imaging centers listed here.

​

​Order Full Body MRI - $1,199:

​Full-body MRI scan with radiologist interpretation and report.

Order Essential Bundle (brain MRI, NeuroGames, genetic analysis) - $1,199:

​The NeuroAge Essential Bundle includes 1) a brain MRI to measure your brain aging and screen preventatively (no contrast or radiation used ); 2) our NeuroAge Games to track your memory and cognition over time; 3) a comprehensive analysis of your genetic risk for neurodegenerative disorders using your existing whole-genome sequencing data.

Order Essential Bundle & Full-Body MRI - $2,099:

​A further discounted package that includes both the NeuroAge Essential Bundle and the Full-Body MRI

Order Blood Biomarkers.

Order NeuroGames.

​

Fueling Longevity Today (FLT)

Science-backed supplements for healthy aging.

Order here.​

​

We know that Prof Nag was offering full body MRI scans this morning, which included via capAI. I suspect that Neuroage will be one of the many capMedic companies being incubated by capAI shortly. This is the mind-boggling (literally) self-learning AI company he was talking about. This alone would make capAI a star UK/USA listed company - but there will I think be a number of these:

NeuroAge wants to reprogramme your brain back to a younger state

NeuroAge Therapeutics, Inc. — investment search application ...

NeuroAge Therapeutics is a San Francisco-based biotech company that uses artificial intelligence to develop personalized therapies aimed at reversing brain aging and treating neurodegenerative diseases such as Alzheimer’s and dementia. Founded in 2022, the company’s approach differs from traditional strategies by targeting the underlying process of brain aging itself, rather than focusing solely on removing toxic protein build-ups after damage has occurred.

Key aspects of NeuroAge Therapeutics:

AI-Driven Drug Discovery: NeuroAge’s platform analyzes large-scale human brain data, including genetics, MRI scans, and cognitive tests, to identify genes and proteins associated with slower brain aging. This enables the design of drugs tailored to rejuvenate the brain based on individual biomarkers.

Personalized Brain Health Assessment: The company offers the NeuroAge Test, which uses AI to integrate MRI, blood biomarkers, cognitive testing, and genetics to predict how quickly an individual’s brain is aging and estimate dementia risk up to 30 years before symptoms appear. Users receive personalized recommendations to slow brain aging and optimize cognitive health.

Clinical Validation: NeuroAge validates its drug candidates in human neurons, brain organoids, and animal models, and is running clinical trials aiming for FDA approval.

Recognition and Funding: NeuroAge has received funding from the Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator and is recognized as an innovator in the longevity and cellular reprogramming biotech sectors.

Leadership: The company was co-founded by Dr. Christin Glorioso, a neuroscientist, and Dr. Priyanka Joshi.

Headquarters:

135 Mississippi St, San Francisco, CA, USA 94107.

NeuroAge Therapeutics stands out for its use of AI to both assess brain aging and develop drugs that address the root causes of neurodegeneration, with the goal of enabling earlier, more personalized interventions for brain health.

A number of very short term traders move around in packs. I notice a few posting here yesterday are now bigging up another stock or two.

I am really happy and privileged to be a serious investor in capAI. We have now had confirmation of other media companies joining Author42, eg "author" (et al) gaming, video and publishing companies - and being launched in the USA as well as in the UK. I strongly suspect 100% revenues from worldwide sales coming to capAI, ie similar deal to Author42. With these media AI companies profits are 90% of the revenues. Today Dr Nag is talking about capAI being conduit for whole body MRI re longevity. We now have close alignment with R42, and are anticipating scientific and medical companies being part of capAI.

These incubator companies will be growing very fast indeed with full automation and very few staff. We will shortly receive great revenues from four media companies while they fast grow. This is in addition to proceeds from "mature" fully hatched companies when they are sold on. This I fully believe is an enormous company about to be rolled out. A number of unicorns shortly in development. I'm staying here and not day trading. I know that many others are also doing the same here. My greetings to fellow investors in this expertly led and major AI company.

5p I'd say also. We'd likely have four different media companies in total, and 2-4 medical companies by Christmas. The four media companies all producing revenues rather massively by them, which would be able to finance the medical companies. That's the way I'm looking at it. Depends on terms of deals etc, so how long is a piece of strong etc at this stage. Imho. Each market will be disruptive and massive. Maybe 5p is conservative. Imho

So many buys coming in now, and at 0.507. All are in real time.

Didn't know there will also be a cap Finance. Have you got a link for that? Many thanks.

I million buy at 50p just gone through -real time.

Delayed buys starting now!

Are we on NT yet? I think that MMs are running out of stock, as warrants probably now gone.

Lots of 1mn buys earlier. That RNS is an absolute cracker. We'll soon go really right up, imho.

Revenue coming in probably from four media companies to be incorporated - and for the UK and the USA. Institutions etc. Then, we start on the medical companies.

Apologies for slight spelling mistakes in previous post - I'm writing quickly from my small mobile, but hope people get the drift and the way this company is very rapidly growing.

Jam96p: thank you! What you have just post re Superbio is a mega worldwide scientific breakthrough with corresponding IP. This is discovery of genome sequences "at scale" - huge

medical and technological advances can be made with this.

Goodlife: I agree with you as well. Author42 on its own is great, and with its own IP. It is different from the other, limited number, of similar companies. Author42 is capable of doing major new things in the writing area, and in a rapidly growing market.

I am delighted with the Author42 - both as a new company and the quality of the deal in capAI's favour. It is just great in its own right.

But we know also, in addition to Author42, that we have a number of othet media and medicine companies to be added to capAI in the near future

This is already a great company with world-class leadership. Current shate price is plain daft.

Hi Nero, spot on. It's all about patience. We have one major publishing company in the bag, with revenues starting quite soon. That makes CPAI immediately stand out against so many "jam tomorrow" companies. We know from the recent RNS that Dr Nag has said "something even more exciting" is to follow. On the grapevine that appears to be the "AI gaming" company. If we have the same terms as Author42, then the revenues here will more than double. I "suspect" then that we'll also soon have Superbio to add and to incubate. This company is of UK/European AI significance. It is actually quite mind-boggling. BUT don't look at screen all day, we can just be patient, knowing that much work is being done under the bonnet.

AI is an absolute revolution, a monster in the making, as is this company. I for one am most grateful to be invested in this company, at the same time as I'm writing my second book (!).

A little bit of patience, that's all. You are entirely correct - thank you.

I like the look of the Chairman's buy of 6% of the company, plus the £5mn buy yesterday.

The buys this morning have been relentless, and continue apace.

I anticipate that David Brown will come up with an excellent acquisition in the near future. I am 90% invested in another great company, but have 10% here as well. AI in Fintech is a major market. Personally I think this will do very well.

Lovely that we have worldwide rights to the Author42 platform and first revenues from this in the near future.

Prof Nag is even more excited about some other addition to capAI's company portfolio. These media ones are really great for revenues. Supposing we can also get a similar transformative deal, say with media and gaming in the near future? These four possible/probable media ones should make the company a lot of money. That deal yesterday was fantastic! Supposing we initially have say 3-4 of these in total, and then use those to fund the scientific AI ones from our income. We'd have a lot of money coming in and the funds to incubate several -and without significant dilution. I can foresee a time quite soon where we'll again have a stock shortage and very large share price increases.

Happy to sit and wait. It will happen - and soon, imho.